Recent Updates on GLP-1 Therapies

GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP Professor, Pharmacy Practice and Clinical Pharmacist Midwestern University GET CE FOR LISTENING! Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription. All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more! The Pharmacist CE Subscription includes: - Compliance and licensure CE - GameChangers Clinical Updates - Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now! PRACTICE RESOURCE Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit: If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations. 2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment. Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated. 0.1 CEU/1.0 Hr UAN: 0107-0000-26-081-H01-P Initial release date: 3/9/2026 Expiration date: 3/9/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram